Fifth Third Wealth Advisors LLC Acquires 3,204 Shares of Boston Scientific Co. (NYSE:BSX)

Fifth Third Wealth Advisors LLC boosted its holdings in Boston Scientific Co. (NYSE:BSX) by 11.2% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 31,749 shares of the medical equipment provider’s stock after buying an additional 3,204 shares during the quarter. Fifth Third Wealth Advisors LLC’s holdings in Boston Scientific were worth $2,836,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in BSX. Pines Wealth Management LLC bought a new position in Boston Scientific during the fourth quarter valued at approximately $798,000. Accurate Wealth Management LLC bought a new position in shares of Boston Scientific during the 4th quarter valued at $228,000. Tlwm boosted its stake in shares of Boston Scientific by 3.9% in the 4th quarter. Tlwm now owns 14,062 shares of the medical equipment provider’s stock worth $1,256,000 after buying an additional 531 shares during the last quarter. West Oak Capital LLC bought a new stake in shares of Boston Scientific in the fourth quarter worth $29,000. Finally, Rosenberg Matthew Hamilton lifted its holdings in Boston Scientific by 15.8% in the fourth quarter. Rosenberg Matthew Hamilton now owns 1,820 shares of the medical equipment provider’s stock valued at $163,000 after acquiring an additional 248 shares during the period. 89.07% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, EVP John Bradley Sorenson sold 4,119 shares of the business’s stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $90.02, for a total value of $370,792.38. Following the completion of the sale, the executive vice president now owns 35,319 shares in the company, valued at approximately $3,179,416.38. The trade was a 10.44 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Arthur C. Butcher sold 14,010 shares of Boston Scientific stock in a transaction on Monday, November 25th. The shares were sold at an average price of $89.27, for a total value of $1,250,672.70. Following the sale, the executive vice president now directly owns 978 shares of the company’s stock, valued at approximately $87,306.06. This trade represents a 93.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 29,989 shares of company stock worth $2,702,261 over the last quarter. Company insiders own 0.50% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently issued reports on BSX shares. Morgan Stanley boosted their target price on shares of Boston Scientific from $92.00 to $100.00 and gave the company an “overweight” rating in a research report on Thursday, October 24th. Truist Financial lifted their price objective on Boston Scientific from $100.00 to $110.00 and gave the company a “buy” rating in a research report on Wednesday, December 18th. Sanford C. Bernstein raised their target price on shares of Boston Scientific from $92.00 to $100.00 and gave the stock an “outperform” rating in a research note on Thursday, October 24th. Deutsche Bank Aktiengesellschaft upgraded shares of Boston Scientific from a “hold” rating to a “buy” rating and set a $108.00 price target for the company in a research report on Friday, January 10th. Finally, Evercore ISI raised their price objective on shares of Boston Scientific from $82.00 to $90.00 and gave the company an “outperform” rating in a research report on Tuesday, October 1st. Three research analysts have rated the stock with a hold rating, twenty have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Boston Scientific presently has a consensus rating of “Moderate Buy” and an average target price of $97.26.

Boston Scientific Price Performance

Boston Scientific stock opened at $95.54 on Wednesday. Boston Scientific Co. has a 12-month low of $59.61 and a 12-month high of $97.13. The company has a current ratio of 1.48, a quick ratio of 1.02 and a debt-to-equity ratio of 0.44. The firm has a 50-day moving average price of $90.36 and a 200-day moving average price of $84.15. The firm has a market capitalization of $140.81 billion, a PE ratio of 78.96, a price-to-earnings-growth ratio of 2.67 and a beta of 0.80.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, October 23rd. The medical equipment provider reported $0.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.59 by $0.04. The business had revenue of $4.21 billion during the quarter, compared to the consensus estimate of $4.04 billion. Boston Scientific had a net margin of 11.26% and a return on equity of 17.23%. The firm’s quarterly revenue was up 19.3% compared to the same quarter last year. During the same quarter last year, the firm earned $0.50 earnings per share. As a group, equities research analysts forecast that Boston Scientific Co. will post 2.46 EPS for the current year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.